Back to AMRN Stock Lookup
Pages: 1 2 »» Last Page

Amarin Corp plc (AMRN) – Press Releases

Jun 11, 2016 11:00 AM Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Jun 6, 2016 07:30 AM Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Jun 1, 2016 08:00 AM Amarin to Present at the Jefferies 2016 Global Healthcare Conference
May 31, 2016 01:30 PM Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
May 20, 2016 10:50 AM Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
May 11, 2016 07:30 AM Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
May 5, 2016 07:00 AM Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
Apr 28, 2016 07:43 AM Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
Apr 4, 2016 07:00 AM New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies
Mar 31, 2016 07:00 AM Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa(R) in Patients With Elevated Triglycerides Despite Statin Therapy
Mar 9, 2016 12:30 PM Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation
Mar 8, 2016 04:13 PM Amarin's Right to Promote Vascepa(R) Off-Label Affirmed Under First Amendment Litigation Settlement Terms
Feb 25, 2016 07:00 AM Amarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations
Feb 18, 2016 08:00 AM Amarin to Report Fourth Quarter and Full-Year 2015 Results and Host Conference Call on February 25, 2016
Feb 17, 2016 08:00 AM Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation
Jan 21, 2016 07:56 AM Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer
Jan 11, 2016 07:00 AM Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook
Dec 14, 2015 06:00 AM Amarin Added to NASDAQ Biotechnology Index
Dec 2, 2015 06:00 AM Amarin to Present at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference
Nov 30, 2015 08:00 AM Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors
Nov 24, 2015 06:00 AM Amarin to Present at the 27th Annual Piper Jaffray Healthcare Conference
Nov 20, 2015 06:00 AM Amarin Announces Agreement to Purchase $16.2 Million of Its Existing Exchangeable Notes and Pricing of $31.3 Million of New Exchangeable Notes
Nov 9, 2015 08:07 AM EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study
Nov 4, 2015 07:00 AM Amarin Reports Third Quarter 2015 Financial Results and Provides Update on Operations
Oct 28, 2015 07:00 AM Amarin to Report Third Quarter 2015 Results and Host Conference Call on November 4, 2015
Sep 2, 2015 07:00 AM Amarin to Present at the Rodman & Renshaw 2015 Global Investment Conference
Aug 27, 2015 07:00 AM Amarin Announces Encore Presentation of Results of the Apolipoprotein C-III Post-Hoc Analysis From MARINE and ANCHOR Studies of Vascepa(R) at the European Society of Cardiology (ESC) 2015 Annual Congr
Aug 11, 2015 07:00 AM Amarin Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives
Aug 7, 2015 10:49 AM First Amendment Decision a Win for Amarin and Physician Plaintiffs
Aug 6, 2015 04:01 PM Amarin Reports Second Quarter 2015 Financial Results and Provides Update on Operations
Aug 5, 2015 04:27 PM Poseida Therapeutics, Inc., Expands Board of Directors
Aug 5, 2015 04:27 PM Poseida Therapeutics, Inc., Expands Board of Directors
Jul 31, 2015 07:00 AM Amarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the American Society for Preventive Cardiology (ASPC) Annual Cardiovascular Disease Prevention Conference and the
Jul 30, 2015 07:00 AM Amarin to Report Second Quarter 2015 Results and Host Conference Call on August 6, 2015
Jul 9, 2015 10:00 AM Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
Jun 11, 2015 07:00 AM New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago
Jun 8, 2015 07:00 AM New In Vitro Eicosapentaenoic Acid Study Data Presented June 6 at the American Diabetes Association Scientific Sessions in Boston
May 28, 2015 02:29 PM Amarin Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market Exclusivity for Vascepa(R) (Icosapent Ethyl) Capsules
May 26, 2015 05:00 PM Amarin to Present at the Jefferies 2015 Global Healthcare Conference
May 8, 2015 06:00 AM Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations
May 5, 2015 05:00 PM Amarin to Report First Quarter 2015 Results and Host Conference Call on May 8, 2015
Apr 8, 2015 08:00 AM Amarin and Non-Profit, Walk with a Doc Partner to Expand National Health Awareness Efforts
Mar 16, 2015 04:30 PM New In Vitro Study Presented at the American College of Cardiology Meeting Suggests Omega-3 Fatty Acid EPA Pre-Treatment Reduces Oxidative Damage and May Provide Atheroprotective Benefit Versus Other
Mar 6, 2015 05:00 AM Amarin Announces $52.8 Million Private Placement
Dec 15, 2014 07:10 AM Annual Changes to the NASDAQ Biotechnology Index
May 15, 2014 05:00 AM Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
May 9, 2014 07:00 AM Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
Mar 31, 2014 04:30 PM Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
Feb 27, 2014 04:01 PM Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
Feb 21, 2014 04:01 PM Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
Pages: 1 2 »» Last Page

Back to AMRN Stock Lookup